Toll-like receptor 9 interaction with CpG ODN – An *in silico* analysis approach

Wei Zhou¹, Yan Li²†, Xichun Pan³, Yuan Gao³, Beiping Li¹, Zhengliang Qiu⁴, Long Liang¹*, Hong Zhou³* and Junjie Yue¹*

**Abstract**

**Background:** Toll-like receptor 9 (TLR9) recognises unmethylated CpG DNA and activates a signalling cascade, leading to the production of inflammatory cytokines such as TNF-α, IL-1, IL-6 and IL-12 via the adaptor protein MyD88. However, the specific sequence and structural requirements of the CpG DNA for the recognition of and binding to TLR9 are unknown. Moreover, the 3D structures of TLR9 and the TLR9-ODN complex have not been determined. In this study, we propose a reliable model of the interaction of the TLR9 ECD with CpG ODN using bioinformatics tools.

**Results:** The three-dimensional structures of two TLR9 ECD-CpG ODN complexes were constructed using a homology modelling and docking strategy. Based on the models of these complexes, the TLR9 ECD-CpG ODN interaction patterns were calculated. The results showed that the interface between the human TLR9 and the CpG ODN molecule is geometrically complementary. The computed molecular interactions indicated that LRR11 is the main region of TLR9 that binds to CpG ODN and that five positively charged residues within LRR11 are involved in the binding of the TLR9 ECD to the CpG ODN. Observations in the close-up view of these interactions indicated that these five positively charged residues contribute differently to the binding region within the TLR9 ECD-CpG ODN complex. 337Arg and 338Lys reside in the binding sites of ODN, forming hydrogen bonds and direct contacts with the CpG ODN, whereas 347Lys, 348Arg, and 353His do not directly contact the CpG ODN. These results are in agreement with previously reported experimental data.

**Conclusion:** In this study, we present two structural models for the human and mouse TLR9 ECD in complex with CpG ODN. Some features predicted by this model are consistent with previously reported experimental data. This complex model may lead to a better understanding of the function of TLR9 and its interaction with CpG ODN and will improve our understanding of TLR9-ligand interaction in general.

**Background**

Toll-Like Receptors (TLRs) recognise pathogen-associated molecular patterns (PAMPs) and are thought to be the key sensors of invading microbes in the innate immune system. Thirteen TLR members (TLR1-13) have been identified that are expressed on the cell surface (TLR 1, 2, 4, 5, and 6) or within the endosomal compartment (TLR 3, 7, 8, and 9). The surface-expressed TLRs primarily recognise structural
components of pathogens, while the endosomal TLRs are dedicated to recognising nu-
cleic acids [1].

The TLRs are type I integral membrane glycoproteins that consist of a pathogen-
binding ectodomain (ECD) and a cytoplasmic signalling domain, joined by a single
transmembrane helix [2]. Pathogen-binding ectodomains of mammalian TLRs com-
prise 19–25 extracellular leucine-rich repeats (LRRs) and a cytoplasmic toll/inter-
leukin (IL)-1R (TIR) domain [3]. LRRs containing 24–29 amino acids are
responsible for ligand recognition and binding, and the TIR domain is responsible
for downstream signalling.

TLR9 is a receptor for sensing bacterial DNA/CpG-containing oligodeoxynucleotides
(CpG ODN) within the endosomal compartment [4]. Internalised CpG DNA within the
endosome initiates TLR9-mediated signalling via the sequential recruitment of MyD88,
IRAK and TRAF6, which in turn activate important downstream transcription factors
such as NF-κB and AP-1. These transcription factors induce the expression of inflam-
matory cytokines such as TNF-α, IL-6, IL-1β and IL-12 [5]. There are 25 LRRs in the
ECD of human TLR9 (hTLR9); however, it is unknown which LRRs recognise and bind
CpG DNA and which specific amino acids within the LRR are the most important for
mediating recognition and binding.

Many studies have explored the mechanism of CpG DNA binding to its receptor. In
2003, LRRs 2, 5, and 8, bearing long insertions at position 10 following the consensus
Asn residue, were thought to be the recognition sites of TLR9 [6]. LRR8 contains a
6-residue insert, similar to a motif identified in a protein that directly binds to
 unmethylated CpG dinucleotide sequences; thus, LRR8 was thought to be a site of CpG
DNA recognition by TLR9 [7]. It was recently proposed that cleavage of the ECD
occurs in mouse TLR9 (mTLR9) and that the fragment starting from LRR15 mediates
ligand recognition [8,9].

In 2009, Peter et al. found that LRRs 2, 5, and 8 contribute to CpG DNA-induced ac-
tivation of TLR9 and that deletion of the inserted sequences at position 10 leads to a
loss of receptor binding ability. They also identified a positively charged region of the
N-terminus that was essential for CpG DNA-induced TLR9 activation [10]. Another
finding indicated that two variants of hTLR9, Pro99Leu within LRR2 and Met400Ile
within LRR13, are associated with altered receptor function with regard to NF-κB acti-
vation and cytokine induction [11], suggesting that the N-terminal fragment preceding
LRR14 also binds to CpG ODN.

Although the above reports provide useful information about the recognition
and binding of CpG ODN to TLR9, detailed information about the precise se-
quence and structural requirements of the TLR9 interaction with CpG ODN is
lacking. It remains unclear which LRR on TLR9 is the binding site(s) for the CpG
ODN are which residues within the LRR directly contribute to the binding, pri-
marily because of the lack of structural information on either TLR9 or the TLR9-
ODN complex.

The aim of this study is to define a structural model for the TLR9-CpG ODN com-
plex and to describe the interaction between TLR9 and CpG ODN using computational
methods. Therefore, we can identify and characterise the LRR region within hTLR9 that
binds to CpG ODN with the higher affinity and further determine which specific resi-
dues are critical for ligand binding.
Results

Residues within LRR11 in hTLR9 provide the greatest number of interactions with CpG ODN

The TLR9-ODN complex was modelled in three steps. First, we predicted the structure of the TLR9 ECD using a homology modelling approach. Second, we built the ODN in substrate mode. Third, we docked the CpG ODN substrate to the protein model.

The computed hTLR9 ECD model revealed a horseshoe-shaped assembly that adopted an irregular solenoid structure with some disordered regions. The compatibility of the hTLR9 ECD structure with the amino acid sequence was assessed by the Profiles-3D program in Discovery studio 3.0. The Verify Score of this predicted hTLR9 ECD model was 275.1, which is higher than the Verify Expected Low Score (164.1). This result indicates that the model is of acceptable quality.

The default protein-DNA docking protocol implemented in Hex 6.12 was used for the docking runs. The final complex model was characterised in terms of the interaction features to improve our understanding of the mechanism of hTLR9-CpG ODN recognition. The interaction pattern showed that the hTLR9 ECD-CpG ODN interaction sites were located close to the central region of the hTLR9 ECD (Figure 1). The interface between the receptor and the CpG ODN molecule was geometrically complementary. The interface area of the modelled complex was approximately 1790 Å², with a buried surface area of 1720±760 Å², suggesting that the complex had the “standard-size” interface of a protein and single-stranded DNA complex [12].

Because of the considerable size of CpG ODN, the ligand-binding region of hTLR9 contained many residues. The residues involved in the protein-nucleic acid interface of the hTLR9 ECD-CpG ODN complex were determined on the basis of the buried surface area. There were about 25 residues that lost their accessible surface in the hTLR9-CpG ODN complex. These residues constituted a large contact area to bind the CpG ODN molecule. The interface area contributed by the protein was 840 Å², which was 46.9% of the total interface area. Among the 25 residues of hTLR9, residues 224Tyr,

Figure 1 The structure of the hTLR9-ODN complex obtained by the Protein-DNA docking method. The structure of hTLR9 ECD is shown in carton; helical residues and beta sheet residues are coloured yellow, and the loop and unassigned residues are coloured green. LRR11 is coloured magenta. CpG ODN is shown in rainbow sticks.
248Val, 290Val, 312Val, 314Asp, 337Arg, 338Lys, 340Asn, 364Val, 365Ala, 367Lys, 392Met, and 397Arg were important for ligand recognition, and they established more direct and closer contact with the CpG ODN molecule.

In their review, Rohs et al. proposed a new theory regarding the origin of specific recognition between proteins and DNA [13]. They hypothesised that hydrogen bonds and hydrophobic contacts are principally responsible for the recognition specificity. Hydrogen-bond interactions are likely the main force dictating DNA sequence reading by proteins [14]. The hydrophobic bases are more exposed in single-stranded DNA than in dsDNA, leading to more hydrophobic interactions [15,16]. We examined how these interactions affect the binding of protein and DNA by analysing the distribution of these interactions throughout the hTLR9 ECD-CpG ODN complex.

There are 7 intermolecular hydrogen bonds and 29 hydrophobic interactions in the hTLR9 ECD-CpG ODN complex. The hydrogen bonds and hydrophobic interactions in this complex model are listed in Table 1 and Table 2, respectively. It has been shown that 90% of the protein-nucleic acid hydrogen bonds have the donor group on the protein and the acceptor group on the DNA [12]. Similarly, five of the seven hydrogen bonds in the hTLR9 ECD-CpG ODN complex have the donor group on the protein, and the other two have the donor group on the ODN.

Some residues within LRR11, such as 335Asn, 337Arg, 338Lys, and 340Asn, formed more strong interactions with ODN 1826. Thus, LRR11 may be the main region of hTLR9 that binds to CpG ODN. This result is consistent with the experimental data in a prior report. We previously demonstrated that LRR11 peptide could bind to CpG ODN with high affinity, significantly decreasing CpG ODN internalisation and

| Amino acid | Atoms | Nucleotide | Atoms |
|------------|-------|------------|-------|
| TYR224     | CZ    | C8         | C5'   |
| VAL248     | CG1   | C8         | C5'   |
| VAL290     | CG2   | G9         | C5'   |
| VAL312     | CB    | G6         | C2    |
| VAL312     | CG1   | C8         | C5'   |
| VAL312     | CG2   | A7         | C2    |
| ASP314     | CB    | G9         | C5'   |
| ARG337     | CD,CZ | A4         | C2,C5,C6 |
| ARG337     | CZ    | T5         | C2    |
| ARG337     | CB,CZ | G6         | C2,C4,C5,C6 |
| LYS338     | CD    | A7         | C2    |
| LYS338     | CD,CE | C8         | C2    |
| LYS338     | CE    | G9         | C2    |
| ASN340     | CG    | T10        | C5'   |
| VAL364     | CG1   | C3         | C5    |
| ALA365     | CB    | A4         | C6    |
| LYS367     | CE    | T5         | C4,C5 |
| MET392     | CE    | C3         | C2,C3,C5' |
| ARG397     | CZ    | T11        | C5'   |
subsequent CpG ODN/TLR9 signalling. The hTLR9 mutant with a deletion in LRR11 conferred decreased responses to CpG ODN in HEK293T cells. These results suggest that LRR11 strongly binds to CpG ODN and that LRR11 may be the main region of hTLR9 that binds to CpG ODN [17].

Five positively charged residues of LRR11 contribute differently to the binding of hTLR9 to CpG ODN

Analysis indicates that the interfaces where protein interacts with DNA are highly enriched in positive charges and almost devoid of negative charges [14]. The positively charged lysine and arginine account for 41% of the average interface area, while the negatively charged aspartic acid and glutamic acid only account for 4% of the interface area [12]. In the predicted hTLR9 ECD-CpG ODN complex model, LRR11 was the main region of hTLR9 binding to CpG ODN. Sequence analysis revealed there are five positively charged residues within LRR11 of hTLR9.

In our previous report [17], mutational studies indicated that a mutation at any one of the five residues drastically decreased the affinity of LRR11 for ODN, and among the five single mutations, R337S and K338N led to the most severe losses of LRR11-ODN binding. These results demonstrated that all five positively charged residues in LRR11 were essential for the high affinity binding of LRR11 with CpG ODN but that 337Arg and 338 Lys contributed more than the other residues to the binding affinity.

The docked structure provided insight into the role of the five positively charged residues in the interaction with the ODN. The computed hTLR9 ECD-CpG ODN complex showed that Arg337 and Lys338 were located on the concave face of the horseshoe and that they were the binding sites of the ODN. In the closed view of the binding region within the complex, the hTLR9 ECD anchored the ODN strand with Arg337 and Lys338; the other three positively charged residues Lys347, Arg348 and His353 were not directly involved in binding to the ODN (Figure 2) but were located in the insertion loop that connected the β-face with the convex surface. The molecular interaction details showed that Arg337 and Lys338 contributed the main hydrogen bonds in the hTLR9 ECD-CpG ODN complex and formed direct hydrophobic contacts with the ODN. Although the three other positively charged residues, Lys347, Arg348 and His353, did not directly interact with the ODN molecule, mutations at these positions caused rearrangement of the loop structure of LRR11. The effect of this rearrangement would propagate to the nearby LRRs, distorting the shape of the TLR9 interface surface.

Table 2 Hydrogen bond interactions observed in the complex between human TLR9 and the ODN

| Donor     | Acceptor     | Distance | Angle |
|-----------|--------------|----------|-------|
| A:TYR224:HH | SDG9:OP1 | 2.18     | 121.3 |
| A:ARG337:HH | SDTS:O2 | 2.48     | 86.1  |
| A:LYS338:HH | SD8:O2 | 2.06     | 126.2 |
| A:LYS338:HH | SDG9:O3 | 2.43     | 107.2 |
| A:LYS367:HH | SDTS:O4 | 1.67     | 129.8 |
| S:DC3:H2 | A:ARG311:O  | 2.21     | 165.8 |
As seen in all protein-DNA complexes, the interface is geometrically complementary between the protein and DNA molecules, ensuring an optimal intermolecular contact [14]. The complementary interface between the hTLR9 ECD and the ODN molecule is essential for their interaction. The shape of the TLR9 interface surface serves as a discriminating factor for ODN recognition; any alteration of TLR9 surface properties would influence ligand binding.

A similar phenomenon was reported by others for the D299G polymorphism of TLR4. The D299G SNP is located in the loop region of LRR10, on the convex face of TLR4. In a recent report, the substitution of more flexible and neutral residues, such as Asp299 to Gly299, induced a structural change in the loop region of LRR10-12, which caused the modulation of TLR4 surface properties and affected ligand binding [18].

**There are more hydrophobic interactions between mouse TLR9 and the CpG ODN than between human TLR9 and the CpG ODN**

Species-specific ligand binding exists for many TLRs. For example, human and murine TLR2 can be activated by different lipoproteins [19]. Species-specific differences have been observed in the recognition of LPS between mammalian species [20-23]. Similarly, TLR9s in different vertebrate species have distinct CpG ODN specificities; human and mouse TLR9s display distinct response profiles to CpG-ODN (24, 25). CpG-ODN containing a GTCGTT motif preferentially activate hTLR9, whereas CpG-ODN with a GACGTT motif more strongly activate mTLR9. Because it contains a GACGTT motif, CpG-1826 more potently activated mTLR9 than it activated hTLR9 [24,25].

The factors underlying the receptor’s species specificity remain unknown. The cause of the activation discrepancy between human and mouse TLR9 for CpG ODN –1826 is still unclear. To this end, comparative homology modelling and docking studies were employed to construct a mTLR9 ECD-CpG ODN complex model. We compared the structure of the mTLR9 ECD-CpG ODN complex with that of hTLR9 ECD-CpG ODN
complex and analysed the changes in the intermolecular interactions of the two complexes.

The pattern of mTLR9 interaction with the CpG ODN exhibited both similarities to and differences with that of hTLR9 (Figure 3). The hydrogen bonds and hydrophobic interactions in the mTLR9 ECD-CpG ODN complex are listed in Table 3 and Table 4, respectively.

The predicted mTLR9 ECD-CpG ODN complex had an interface area of about 1945 Å², which is greater than that of the hTLR9 ECD-CpG ODN complex. The interface area measures the area of protein and nucleic acid surface that is buried in contacts between the two macromolecules. The extent of the contact between two macromolecules is indicated by the size of interface area. In the mTLR9 ECD-CpG ODN model, 31 amino acid residues of mTLR9 and 13 nucleotide residues of CpG ODN 1826 were included in the interface. Among the 31 residues of mTLR9, 6 residues formed hydrogen bonds to the CpG ODN, while 13 residues established hydrophobic contacts with the CpG ODN. More accessible interface area increased the probability of an interaction between TLR9 and CpG ODN.

Seven intermolecular hydrogen bonds directly linking the TLR9 protein to the CpG ODN were observed for both complexes, while more hydrophobic contacts were observed in the mTLR9 ECD-CpG ODN complex (Table 5). Since the difference in hydrophobic interactions was great, the increased number of intermolecular hydrophobic contacts might promote binding stability. These results indicate that mTLR9 has a tighter binding with CpG ODN 1826 compared to hTLR9; hence, we hypothesised that the disparity in the number of hydrophobic interactions may be the primary reason for the marked differences in CpG-ODN 1826-induced activation of the two TLR9s.

Similarly to hTLR9, residues within LRR11 in mTLR9 provided more direct contacts to the CpG ODN molecule. In contrast to hTLR9, Arg-335 within LRR11 in mTLR9 increased the hydrophobic interactions between mTLR9 and CpG ODN 1826 (Table 3). This residue was likely one of the main reasons why mTLR9 was more responsive to ODN 1826.

Figure 3 Proposed mTLR9 ECD-CpG ODN complex. Both the mTLR9 ECD and the CpG ODN are shown in cartoon. The N-terminus (NT) and C-terminus (CT) of the mTLR9 ECD are indicated, with LRR11 highlighted in magenta.
Discussion

Although TLR9 is known to be the receptor for CpG-DNA by directly engaging the ligand, the precise sequence and structural requirements of TLR9 to promote binding are unknown. Moreover, it is unclear which residues recognise and bind the CpG DNA ligand and which LRR is the binding site(s) for CpG DNA or is involved in the binding site(s). There are no crystal structure data for TLR9; in order to investigate how TLR9 interacts with CpG ODN, the 3D structure of the TLR9 ECD was constructed using homology modelling. Homology modelling, also referred to as comparative modelling, is currently the most accurate computational method for protein structure prediction. A limitation of homology modelling is that the quality of the predicted model strongly depends on the sequence identity between the target and the template.

The predicted hTLR9 ECD-CpG ODN model suggested that hydrogen bond interactions and hydrophobic contacts between hTLR9 and ODN 1826 play key roles in their recognition and binding. Residues within LRR11 in hTLR9 provided more interactions with CpG ODN 1826 than other LRRs. This result indicates that LRR11 may be the main region of hTLR9 binding to the CpG ODN. This conclusion is in agreement with results from our previously published experimental data [17].

The model not only identified the binding sites for CpG-ODN but also provided a structural basis for the species-specific ligand binding. In our observations, the mTLR9 ECD-CpG ODN complex had greater interface area compared with the hTLR9 ECD-

Table 3 Hydrophobic interactions observed in the complex between mouse TLR9 and the ODN

| Amino acid | Atoms       | Nucleotide | Atoms       |
|------------|-------------|------------|-------------|
| Tyr224     | CE1,CZ      | C13        | C3          |
| Val248     | C1          | T14        | C7          |
| Glu287     | CB,CG,CD    | T14        | C4,C5,C7    |
| Ser311     | CB          | T14        | C4          |
| Ser311     | CB          | G15        | C6          |
| Val312     | CG2         | C12        | C5          |
| Val312     | CB,CG1,CG2  | C13        | C5, C6      |
| Val312     | CB,CG1      | T14        | C4          |
| Thr334     | CB,CG2      | G18        | C4',C1'     |
| Thr334     | CB,CG2      | T19        | C5',C4'     |
| Arg335     | CA,CG1,CG2,CD | A16   | C2,C6      |
| Arg335     | CB,CG1,CD,CZ | C17     | C2,C4      |
| Arg335     | CB,CG2      | G18        | C2          |
| Arg337     | CB,CG1,CD,CZ | G15     | C2,C6      |
| Arg337     | CZ          | C17        | C4',C5'     |
| Lys338     | CB,CG       | C13        | C4          |
| Lys338     | CG          | T14        | C2          |
| Phe343     | CE1         | T10        | C5'         |
| Val364     | CG2         | G18        | C5'         |
| His397     | CG,CD2,CE1  | T10        | C7          |
| His397     | CE1         | G9         | C2',C3'     |
| Gln399     | CD          | G9         | C5'         |

Zhou et al. Theoretical Biology and Medical Modelling 2013, 10:18
http://www.tbiomed.com/content/10/1/18
CpG ODN complex and provided more hydrophobic interactions. This result could explain why CpG ODN 1826 activates mTLR9 more potently than hTLR9.

In this study, a modelling approach was successfully applied to generate the structures of hTLR9 and mTLR9 ECDs. The predicted model of the TLR9-ODN complex provides us with features that are consistent with the experimental data and can be considered a rough approximation of how TLR9 might interact with its nucleic acid substrate. The docked TLR9-ODN complex model provides a structural framework for interpreting experimental data and further understanding the TLR9 signal transduction process. Finally, these results open new avenues for the computer-aided design of potential inhibitors or antagonists of the CpG DNA–TLR9 signalling pathway.

Table 4 Hydrogen bond interactions observed in the complex between mouse TLR9 and the ODN

| Donor     | Acceptor       | Distance | Angle |
|-----------|----------------|----------|-------|
| A:TYR224HH| S:DC13:OP1     | 2.41     | 133.1 |
| A:TYR224HH| S:DC13:O5*     | 1.84     | 149.3 |
| ASER311HG | S:DG15:O6      | 2.11     | 111.5 |
| A:LYS338HZ2| S:DT14:O2     | 2.28     | 124.7 |
| A:ASN370HD22| S:DT10:OP1    | 2.15     | 130.5 |
| A:LYS392HZ1 | S:C17:O3*     | 2.48     | 152.6 |
| S:DG15:H22| A:ARG337NE    | 2.44     | 105.8 |

Zhou et al. Theoretical Biology and Medical Modelling 2013, 10:18 Page 9 of 12 http://www.tbiomed.com/content/10/1/18

Conclusion
By applying molecular modelling and protein docking methods, three-dimensional structures of two TLR9-CpG ODN complexes were built. With these structures, we obtained useful information about the detailed interaction between TLR9 and the ODN ligand. These models provide a novel picture of CpG DNA-TLR9 recognition and binding and elucidate the mechanism underlying the TLR signal transduction process.

Methods
Data sets
Sequences of human TLR9 and mouse TLR9 in FASTA format were retrieved from the public database UniProt/ExPASy (Swiss Bioinformatics Resource) http://expasy.org/tools/ [26], having accession numbers of Q9NR96 and Q9NR96 respectively.

Table 5 TLR9-ODN CpG interfaces

| Protein | Nucleic Acid | Interface area (Å²) | Interface residues | H-bonds | Hydrophobic contacts |
|---------|--------------|---------------------|--------------------|---------|---------------------|
| mTLR9   | ODN CpG      | 1945                | 31                 | 13      | 7                   | 53 |
| hTLR9   | ODN CpG      | 1790                | 25                 | 12      | 7                   | 29 |
CpG ODN 1826 (CpG ODN, 5’-TCCATGACGTTCTGACGTT-3’, the optimal immunostimulatory murine sequence) was used in this study.

Molecular modelling

Searches for reference proteins, sequence alignments and homology modelling were performed in Discovery Studio 2.5 (Accelrys Inc.). A BLAST search of the PDB indicated that the crystal structures of human TLR3, TLR2 and TLR4 ECD were suitable template models for the TLR9 ECD. Although the full-length sequence identity between the TLR9 and the templates is relatively low (26–28%), the presence of highly conserved LRR motifs in the target and templates suggests that the comparative homology modelling of the TLR9 ECD using the TLR3, TLR2 and TLR4 ECD structure was appropriate [27]. For better accuracy, the three-dimensional structures of the ectodomains of TLR9 were created by I-TASSER, which combines the methods of threading, ab initio modelling, comparative modelling and structural refinement. The I-TASSER server is an online platform for protein structure and function predictions. The I-TASSER server employs a fragment-based method. Here, a hierarchical approach to protein structure modelling is used in which fragments are excised from multiple template structures and reassembled based on threading alignments [28]. 3D models are built based on multiple-threading alignments by LOMETS and iterative TASSER assembly simulations. I-TASSER (as ‘Zhang-Server’) was ranked the No. 1 server for protein structure prediction in recent CASP7, CASP8 and CASP9 experiments [29,30].

The final templates selected by I-TASSER were the TLR3 crystal structure (PDB code 2a0z), TLR4 crystal structure (PDB code 3fxi), TLR3 crystal structure (PDB code 1ziw), TLR4 crystal structure (PDB code 2z64), and TLR2 crystal structure (PDB code 2Z7X).

The quality of the predicted structure was evaluated using the Verify Protein (Profiles-3D) protocol. Profiles-3D Verify checks the validity of a protein structure (e.g., a homology model) by measuring the compatibility score of each residue in the given 3D environment. Scores for each residue and the whole protein are reported, and the expected high and low scores for a protein of the same size are given as a reference point [31].

We employed the Biopolymer tools in Discovery Studio 2.5 to build the ODN model. Because TLR9 binds only to single-stranded molecules [32] and the immunostimulatory activity of CpG-DNA depends on its single-stranded (ss) character [33], we modelled the ODN structure as a single-stranded DNA molecule. The single-stranded ODN molecule was generated in B-form using standard helix parameters.

Docking

The program Hex version 6.12 [34] was applied to perform a docking search. In Hex’s docking calculations, the TLR9 ECD was defined as the receptor, and ODN was used as the ligand. The shape plus electrostatic correlation algorithms were used. Other parameters used for the docking process were set to the default values.

The parameters that were used for the docking process via HEX docking software were as follows:

- Correlation type – Shape plus electrostatic correlation
- FFT Mode – 3D fast life
- Grid Dimension – 0.6
Protein–DNA interaction analysis

The interface area of a complex is derived from its atomic coordinates by computing its accessible surface area in solvent and subtracting it from the sum of the accessible surface areas of the isolated components [12]. Accessible surface areas were evaluated with the program SURVOL [35], which implements the Lee and Richards algorithm [36]. Group radii were from ref [37], and the radius of the water probe was 1.4 Å.

A hydrophobic contact is defined as a distance between carbon atoms shorter than 4.5 Å [38]. All hydrophobic contacts between nucleic acid residues and protein residues are listed.

Protein structure illustrations were generated with the PyMOL Molecular Graphics Software [39].

Abbreviations

TLR: Toll-like receptor; NF-κB: Nuclear factor-κB; LRR: Leucine rich repeat; ECD: Ectodomain.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JY, HZ and LL formulated the study. WZ and YL performed the research. BL and YG analysed the data. XP and ZQ participated in the analysis and discussion. JY wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the National Key Program for Infectious Diseases of China (2011ZX10004-001) and the National Natural Science Foundation of China (81071399, 81271887).

Author details

1Beijing Institute of Biotechnology, Beijing 100071, China. 2Hospital No.307 of PLA, The Academy of Military Medical Sciences, Beijing 100071, China. 3College of Pharmaceutical, Third Military Medical University, Chongqing 400038, China. 4Laboratory Animal Center of the Academy of Military Medical Sciences, Beijing 100071, China.

Received: 6 February 2013 Accepted: 10 March 2013 Published: 14 March 2013

References

1. Uematsu S, Akira S. Toll-like receptors (TLRs) and their ligands. Handb Exp Pharmacol 2008, 183:1–20.
2. Bell JK, Mullen GE, Leifer CA. A: Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003, 24:528–533.
3. Xu Y, Tao X, Shen B, Hanng T, Medzhitov R, Manley JL, Tong L: Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 2000, 408:111–115.
4. Barton GM, Medzhitov R: Toll-like receptors and their ligands. Curr Top Microbiol Immunol 2002, 270:81–92.
5. Jin MS, Lee JO: Structures of TLR-ligand complexes. Curr Opin Immunol 2008, 20:414–419.
6. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM: Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003, 24:528–533.
7. Lee JH, Voo KS, Skalnik DG: Identification and characterisation of the DNA binding domain of CpG-binding protein. J Biol Chem 2001, 276:44669–44676.
8. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, Barton GM: The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456:658–662.
9. Park B, Brinkmann NM, Spooner E, Lee CC, Kim YM, Ploegh HL: Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol 2008, 9:1407–1414.
10. Peter ME, Kubarenko AV, Weber AN, Dalpke AH: Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation. J Immunol 2009, 182:7690–7697.
11. Kubarenko AV, Ranjan S, Rautanen A, Mills TC, Wong S, Vannberg F, Neumaier M, Bekeredjian-Ding I, Hill AV, Ahmad-Nejad P, Weber AN: A naturally occurring variant in human TLR9, P99L, is associated with loss of CpG oligonucleotide responsiveness. J Biol Chem 2010, 285(47):36486–36494.
12. Nadassy K, Wodak SJ, Janin J: Structural features of protein–nucleic acid recognition sites. Biochemistry 1999, 38:1999–2017.
Salmonella-type heptaacylated lipid A is inactive and acts as an antagonist of Toll-like receptor 9: a comparative analysis of molecular structure, function and expression. J Mol Biol 2010, 406(1):442–450.

17. Xiong Y, Sundaralingam M: Protein-nucleic acid interaction: major groove recognition determinants. In Encyclopedia of Life Sciences. London: Macmillan Reference Ltd; 2001.

18. Xiong Y, Sundaralingam M: DNA sequence: a theoretical study. J Comput Chem 1992, 13(1):23–36.

19. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Interaction with DNA and Selective Fluorescence Enhancement Induced by ssDNA. Biochemistry 1992, 31(2):363–370.

20. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Interaction between tri-palmitoylated and tri-lauroylated peptides. J Mol Biol 2004, 340(4):611–619.

21. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Interaction between DNA and cationic surfactants: effect of DNA conformation and surfactant headgroup. J Phys Chem B 2008, 112(46):14446–14452.

22. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

23. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

24. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

25. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

26. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

27. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

28. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

29. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

30. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

31. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

32. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

33. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

34. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

35. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

36. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

37. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

38. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

39. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

40. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

41. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

42. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

43. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

44. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

45. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

46. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

47. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

48. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

49. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

50. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

51. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

52. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

53. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

54. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

55. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

56. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.

57. Xiong Y, Zhou Q, Bankier PA, Dunn SP, Sundaralingam M: Structural invariants in protein folding. IUBMB Life 2009, 61(10):737–744.